David F. McDermott, MD

Articles

Dr. McDermott on VEGF/PD-1 Inhibition in RCC

March 5th 2020

David F. McDermott, MD, discusses the research behind combining VEGF inhibitors with PD-1/PD-L1 inhibitors in renal cell carcinoma treatment.

Dr. McDermott on Toxicities of Immunotherapy Combinations in RCC

February 12th 2020

David F. McDermott, MD, discusses the toxicities associated with immunotherapy combinations in renal cell carcinoma.

Dr. McDermott on the Use of PD-1 Inhibitor Combos in mRCC

January 8th 2020

David F. McDermott, MD, discusses the use of PD-1 inhibitors in combination with VEGF inhibitors and CTLA-4 inhibitors in metastatic renal cell carcinoma.

Dr. McDermott on TKI/Immunotherapy Combinations in RCC

November 12th 2019

David F. McDermott, MD, discusses the combination of VEGF TKIs and PD-1 inhibitors in advanced renal cell carcinoma.

Dr. McDermott on the Promise of Pembrolizumab in Non-Clear Cell RCC

June 6th 2019

David F. McDermott, MD, director of the Biologic Therapy Program at Beth Israel Deaconess Medical Center, discusses the promise of single-agent pembrolizumab in advanced non–clear cell renal cell carcinoma.

Dr. McDermott on Single-Agent Versus Combination Immunotherapy in RCC

March 14th 2019

David F. McDermott, MD, director of the Biologic Therapy Program at Beth Israel Deaconess Medical Center, discusses single-agent versus combination immunotherapy in the treatment of patients with renal cell carcinoma.

Dr. McDermott on Single-Agent Pembrolizumab in Advanced RCC

February 19th 2019

David F. McDermott, MD, director of the Biologic Therapy Program at Beth Israel Deaconess Medical Center, discusses single-agent pembrolizumab in the treatment of patients with advanced renal cell carcinoma.

Dr. McDermott on an Analysis of the CheckMate-214 Study in RCC

November 14th 2018

David F. McDermott, MD, director of the Biologic Therapy Program at Beth Israel Deaconess Medical Center, discusses an analysis of the CheckMate-214 study in advanced renal cell carcinoma (RCC).

Dr. McDermott on Novel Immunotherapy Combinations in RCC

January 20th 2018

David F. McDermott, MD, director of the Biologic Therapy Program at Beth Israel Deaconess Medical Center, discusses novel immunotherapy combinations for patients with metastatic renal cell carcinoma (RCC).

Dr. McDermott on Immunotherapy as a Standard of Care in RCC

December 28th 2017

David F. McDermott, MD, director of the Biologic Therapy Program at Beth Israel Deaconess Medical Center, discusses immunotherapy as a standard of care for patients with renal cell carcinoma (RCC).

Dr. McDermott on Single-Agent Nivolumab in RCC

December 14th 2017

David F. McDermott, MD, director of the Biologic Therapy Program at Beth Israel Deaconess Medical Center, discusses nivolumab (Opdivo) as a single-agent for the treatment of patients with renal cell carcinoma.

Dr. McDermott on Nivolumab Plus Ipilimumab in RCC

November 30th 2017

David F. McDermott, MD, director of the Biologic Therapy Program at Beth Israel Deaconess Medical Center, discusses the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) in renal cell carcinoma (RCC).

Dr. McDermott on the Role of VEGF Targeted Therapy in RCC

May 11th 2017

David F. McDermott, MD, director, Biologic Therapy and Cutaneous Oncology Programs, Hematology/Oncology, Beth Israel Deaconess Medical Center, discusses the role of VEGF-targeted therapy in renal cell carcinoma.

Dr. McDermott on Immunotherapy-Related AEs in RCC

April 24th 2017

David F. McDermott, MD, director of the Biologic Therapy Program at Beth Israel Deaconess Medical Center, discusses the immune-related toxicities for patients receiving checkpoint inhibitors for treatment of their renal cell carcinoma.

Dr. McDermott Discusses the Future of Immune Checkpoints in RCC

March 13th 2017

David F. McDermott, MD, Beth Israel Deaconess Medical Center, discusses the future of immunotherapies in the treatment of patients with kidney cancer.

Dr. McDermott on Lessons From the IMmotion150 Trial in RCC

March 8th 2017

David F. McDermott, MD, Beth Israel Deaconess Medical Center, discusses lessons learned from the recent IMmotion150 trial in renal cell carcinoma (RCC). The open-label, randomized study examined the PD-L1 inhibitor atezolizumab (Tecentriq) alone or in combination with bevacizumab (Avastin) versus sunitinib (Sutent) in patients with untreated advanced RCC.

Dr. McDermott on IMmotion150 Trial in RCC

February 22nd 2017

David F. McDermott, MD, Beth Israel Deaconess Medical Center, discusses the recent IMmotion150 trial in Renal Cell Carcinoma (RCC).

Dr. McDermott on VEGF Plus PD-1 in Renal Cell Carcinoma

January 14th 2017

David F. McDermott, MD, Director of Biologic Therapy and Cutaneous Oncology Programs, Hematology and Oncology at the Beth Israel Deaconess Medical Center, discusses the combination of VEGF plus PD-1 in renal cell carcinoma (RCC).

Dr. McDermott on Major Findings of Efficacy and Safety of Nivolumab in RCC

September 7th 2016

David F. McDermott, MD, director of the Biologic Therapy Program at Beth Israel Deaconess Medical Center, discusses the findings of the phase III CheckMate-025 trial of nivolumab (Opdivo) versus everolimus (Afinitor) in renal cell carcinoma (RCC).

Dr. David F. McDermott on Nivolumab in RCC

August 5th 2016